Mesa Laboratories (NASDAQ:MLAB) Sets New 52-Week High - Here's Why

Key Points

• Mesa Laboratories shares reached a new 52-week high of $129.66, despite trading down 0.9% afterward. The stock’s $716.6 million market value and elevated P/E ratio of 152.22 reflect a sharply higher valuation.
• Analysts maintain a generally cautious outlook, with a consensus “Hold” rating and $110 price target—well below the recent trading price. Recent quarterly results included $2.68 in earnings per share and $60.14 million in revenue.
• The company declared a quarterly dividend of $0.16 per share, equal to a 0.5% yield, while institutional investors own 90.6% of outstanding shares. Insiders sold shares recently, primarily to cover tax obligations related to equity awards.

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $129.66 and last traded at $127.6650, with a volume of 153074 shares. The stock had previously closed at $128.93.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MLAB. Wells Fargo & Company upped their target price on Mesa Laboratories from $94.00 to $110.00 and gave the stock an "equal weight" rating in a report on Friday, August 14th. Wall Street Zen lowered Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 15th. Finally, Weiss Ratings upgraded Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Mesa Laboratories has a consensus rating of "Hold" and a consensus price target of $110.00.

Mesa Laboratories Trading Down 0.9%

The company has a market capitalization of $716.63 million, a PE ratio of 152.22 and a beta of 0.92. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.79 and a quick ratio of 1.32. The company's fifty day moving average is $104.42 and its 200-day moving average is $98.63.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.The company had revenue of $60.14 million for the quarter.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories's dividend payout ratio (DPR) is currently 76.19%.

Insider Activity

In related news, CAO Lyndsey Elizabeth Crennen sold 442 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $39,559.00. Following the completion of the transaction, the chief accounting officer directly owned 2,020 shares in the company, valued at approximately $180,790. This trade represents a 17.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO John Sakys sold 2,827 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the transaction, the chief financial officer directly owned 19,785 shares of the company's stock, valued at $1,770,757.50. The trade was a 12.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 15,370 shares of company stock valued at $1,570,213 over the last 90 days. Company insiders own 2.80% of the company's stock.

Institutional Trading of Mesa Laboratories

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MLAB. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in Mesa Laboratories during the second quarter worth $15,507,000. Renaissance Technologies LLC grew its position in shares of Mesa Laboratories by 802.9% in the first quarter. Renaissance Technologies LLC now owns 31,600 shares of the medical instruments supplier's stock valued at $2,794,000 after purchasing an additional 28,100 shares during the period. Irenic Capital Management LP purchased a new stake in shares of Mesa Laboratories during the fourth quarter worth about $1,962,000. Diamond Hill Capital Management Inc. increased its stake in shares of Mesa Laboratories by 15.1% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 141,973 shares of the medical instruments supplier's stock worth $11,145,000 after purchasing an additional 18,592 shares in the last quarter. Finally, Gabelli Funds LLC raised its position in shares of Mesa Laboratories by 12.5% during the 4th quarter. Gabelli Funds LLC now owns 60,724 shares of the medical instruments supplier's stock worth $4,767,000 after purchasing an additional 6,750 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source